Ilyang Pharmaceutical Discloses 2025 CP Performance and 2026 Plan
-
Completed ISO 37001 anti-bribery management system renewal audit (Dec 2025, KCI)
-
2025: Employee CP training, monitoring, whistleblower system operation
-
2026: First surveillance audit planned, continued training and monitoring
KOSPI Filing Information
-
Filing: Status Of Fair Trade Compliance Program Operation (Guidance Disclosure)
-
Company: Ilyang Pharmaceutical (007570)
-
Submission: Ilyang Pharmaceutical Co., Ltd.
-
Receipt: 02-03-2026
-
Under KRX KOSPI Market Division